Lyell Wealth Management LP Increases Stake in Johnson & Johnson (NYSE:JNJ)

Lyell Wealth Management LP increased its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 1.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 7,439 shares of the company’s stock after buying an additional 104 shares during the period. Lyell Wealth Management LP’s holdings in Johnson & Johnson were worth $1,076,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in JNJ. Financial Management Network Inc. increased its position in shares of Johnson & Johnson by 5.9% in the 4th quarter. Financial Management Network Inc. now owns 3,246 shares of the company’s stock valued at $468,000 after purchasing an additional 180 shares during the last quarter. Cannon Financial Strategists Inc. increased its position in shares of Johnson & Johnson by 7.1% in the 4th quarter. Cannon Financial Strategists Inc. now owns 2,701 shares of the company’s stock valued at $391,000 after purchasing an additional 178 shares during the last quarter. Joel Adams & Associates Inc. purchased a new stake in shares of Johnson & Johnson in the 4th quarter valued at approximately $333,000. Global Retirement Partners LLC increased its position in shares of Johnson & Johnson by 5.7% in the 4th quarter. Global Retirement Partners LLC now owns 31,864 shares of the company’s stock valued at $4,608,000 after purchasing an additional 1,719 shares during the last quarter. Finally, Convergence Investment Partners LLC increased its position in shares of Johnson & Johnson by 13.3% in the 4th quarter. Convergence Investment Partners LLC now owns 16,191 shares of the company’s stock valued at $2,342,000 after purchasing an additional 1,897 shares during the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Stock Up 1.7 %

JNJ stock opened at $162.35 on Friday. Johnson & Johnson has a one year low of $140.68 and a one year high of $168.85. The stock has a market capitalization of $390.87 billion, a PE ratio of 24.41, a price-to-earnings-growth ratio of 2.56 and a beta of 0.52. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. The company has a fifty day moving average of $148.93 and a 200-day moving average of $155.88.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, topping the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The company had revenue of $22.52 billion during the quarter, compared to analysts’ expectations of $22.44 billion. During the same quarter last year, the business earned $2.29 EPS. The business’s revenue was up 5.3% on a year-over-year basis. As a group, analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be issued a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.06%. Johnson & Johnson’s dividend payout ratio is presently 74.59%.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on JNJ. Raymond James dropped their price objective on shares of Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating on the stock in a research report on Thursday, January 23rd. Leerink Partners dropped their price objective on shares of Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating on the stock in a research report on Thursday, January 23rd. Wells Fargo & Company dropped their target price on shares of Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating on the stock in a research report on Thursday, January 23rd. Stifel Nicolaus dropped their target price on shares of Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating on the stock in a research report on Thursday, January 23rd. Finally, Wolfe Research began coverage on shares of Johnson & Johnson in a research report on Friday, November 15th. They issued an “outperform” rating and a $190.00 target price on the stock. Nine equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $170.67.

Insider Activity

In related news, Director Mark A. Weinberger purchased 1,000 shares of the business’s stock in a transaction dated Thursday, December 12th. The stock was acquired at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the acquisition, the director now directly owns 1,000 shares of the company’s stock, valued at $147,220. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Timothy Schmid sold 403 shares of the stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total transaction of $62,928.45. Following the completion of the transaction, the executive vice president now owns 15,098 shares of the company’s stock, valued at $2,357,552.70. This represents a 2.60 % decrease in their position. The disclosure for this sale can be found here. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.